Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function

被引:36
作者
Wiegant, Wouter W.
Overmeer, Rene M.
Godthelp, Barbara C.
van Buul, Paul P. W.
Zdzienicka, Malgorzata Z.
机构
[1] Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2300 RC Leiden, Netherlands
[2] Nicholas Copernicus Univ, Coll Med, Dept Mol Cell Genet, Bydgoszcz, Poland
关键词
BRCA2; heterozygosity; XRCC11; hamster V-C8; breast cancer; MMC sensitivity;
D O I
10.1016/j.mrfmmm.2006.03.001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The previously described Chinese hamster cell mutant V-C8 that is defective in Brca2 shows a very complex phenotype, including increased sensitivity towards a wide variety of DNA damaging agents, chromosomal instability, abnormal centrosomes and impaired formation of Rad51 foci in response to DNA damage. Here, we demonstrate that V-C8 cells display biallelic nonsense mutations in Brca2, one in exon 15 and the other in exon 16, both resulting in truncated Brca2 proteins. We generated several independent mitomycin C (MMC)-resistant clones from V-C8 cells that had acquired an additional mutation leading to the restoration of the open reading frame of one of the Brca2 alleles. In two of these revertants, V-C8-Rev 1 and V-C8-Rev 6, the reversions lead to the wild-type Brca2 sequence. The V-C8 revertants did not gain the entire wild-type phenotype and still show a 2.5-fold increased sensitivity to mitomycin C (MMC), higher levels of spontaneous and MMC-induced chromosomal aberrations, as well as abnormal centrosomes when compared to wild-type cells. Our results suggest that Brca2 heterozygosity in hamster cells primarily gives rise to sensitivity to DNA cross-linking agents, especially chromosomal instability, a feature that might also be displayed in BRCA2 heterozygous mutation carriers. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 42 条
[1]   P53 modulates homologous recombination by transcriptional regulation of the RAD51 gene [J].
Arias-Lopez, C ;
Lazaro-Trueba, I ;
Kerr, P ;
Lord, CJ ;
Dexter, T ;
Iravani, M ;
Ashworth, A ;
Silva, A .
EMBO REPORTS, 2006, 7 (02) :219-224
[2]  
Bennett LM, 2000, CANCER RES, V60, P3461
[3]   P53′s double life:: transactivation-independent repression of homologous recombination [J].
Bertrand, P ;
Saintigny, Y ;
Lopez, BS .
TRENDS IN GENETICS, 2004, 20 (06) :235-243
[4]  
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[5]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[6]   Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2 [J].
Buchholz, TA ;
Wu, XF ;
Hussain, A ;
Tucker, SL ;
Mills, GB ;
Haffty, B ;
Bergh, S ;
Story, M ;
Geara, FB ;
Brock, WA .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (05) :557-561
[7]   Interaction of p53 with the human Rad51 protein [J].
Buchhop, S ;
Gibson, MK ;
Wang, XW ;
Wagner, P ;
Sturzbecher, HW ;
Harris, CC .
NUCLEIC ACIDS RESEARCH, 1997, 25 (19) :3868-3874
[8]   The p53 status of Chinese hamster V79 cells frequently used for studies on DNA damage and DNA repair [J].
Chaung, WR ;
Mi, LJ ;
Boorstein, RJ .
NUCLEIC ACIDS RESEARCH, 1997, 25 (05) :992-994
[9]   Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation [J].
Connor, F ;
Bertwistle, D ;
Mee, PJ ;
Ross, GM ;
Swift, S ;
Grigorieva, E ;
Tybulewicz, VLJ ;
Ashworth, A .
NATURE GENETICS, 1997, 17 (04) :423-430
[10]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921